

Idiopathic Pulmonary Fibrosis (IPF)

A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis

Trial Status
Completed

Trial Runs In
2 Countries

Trial Identifier
NCT02648048 2015-003481-81
GB29764

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a single arm, multicenter, open-label, Phase 1b study to evaluate the safety and tolerability of vismodegib in combination with pirfenidone in participants with idiopathic pulmonary fibrosis (IPF) currently being treated with pirfenidone.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT02648048 2015-003481-81 GB29764
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥ 40 Years & ≤ 80 Years

Healthy Volunteers
No
